Dynorphin A (TFA)

CAT:
804-HY-P1333A
Size:
Inquire
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Dynorphin A (TFA) - image 1

Dynorphin A (TFA)

  • UNSPSC Description:

    Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease[1][2].
  • Target Antigen:

    Apoptosis; Caspase; Endogenous Metabolite; Opioid Receptor
  • Type:

    Peptides
  • Related Pathways:

    Apoptosis;GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
  • Applications:

    Neuroscience-Neuromodulation
  • Field of Research:

    Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/dynorphin-a-tfa.html
  • Solubility:

    10 mM in DMSO
  • Smiles:

    OC(C(F)(F)F)=O.OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(NCC(O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)=O)NC([C@H](CC(O)=O)NC([C@H](CCSC)NC([C@H](CC3=CNC4=CC=CC=C34)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H]5N(CCC5)C([C@H](CCCNC(N)=N)NC(CNC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CCSC)NC([C@@H](NC(CNC(CNC([C@@H](N)CC6=CC=C(C=C6)O)=O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC8=CNC9=CC=CC=C89)=O)=O)=O)=O
  • Molecular Weight:

    2261.50
  • References & Citations:

    [1]Zhang, et al.Dynorphin A as a Potential Endogenous Ligand for Four Members of the Opioid Receptor Gene Family. J Pharmacol Exp Ther. 1998 Jul;286(1):136-41.|[2]Aruna Sharma, et al. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair. Int Rev Neurobiol. 2012;102:23-45. |[3]I. N. SINGH, et al. Dynorphin A (1–17) induces apoptosis in striatal neurons in vitro through AMPA/kainate receptor-mediated cytochrome c release and caspase-3 activation. Neuroscience. 2003;122(4):1013-23. |[4]B J Van de Heijning, et al. Dynorphin-A and vasopressin release in the rat: a structure-activity study. Neuropeptides. 1994 Jun;26(6):371-8. |[5]Takayoshi Mamiya, et al. Dynorphin a (1-13) alleviated stress-induced behavioral impairments in mice. Biol Pharm Bull. 2014;37(8):1269-73. |[6]K F Hauser, et al. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol. 1999 Dec;160(2):361-75.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    No Development Reported